Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: Evidence for HDAC2 involvement

Stem Cells

Volumn 32, Issue 1, 2014, Pages 279-289

  Paino, Francesca ^a   La Noce, Arcella ^a   Tirino, Virginia ^a   Naddeo, Asqualina ^a   Desiderio, Vincenzo ^a   Pirozzi, Useppe ^b   De Rosa, Lfredo ^c   Laino, Uigi ^c   Altucci, Ucia ^d   Papaccio, Gianpaolo ^a  

^a Sezione di Istologia e Biotecnologie   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Secondo Ateneo di Napoli   (Italy)

^d Dipartimento di Biochimica Biofisica e Patologia Generale   (Italy)

Author keywords

DPSC; HDAC; Osteogenesis; Valproic acid

Indexed keywords

ALKALINE PHOSPHATASE; BONE SIALOPROTEIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE H3; MESSENGER RNA; OCTAMER TRANSCRIPTION FACTOR 4; OSTEOCALCIN; OSTEOPONTIN; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR NANOG; VALPROIC ACID;

APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; DENTAL PULP STEM CELL; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE SILENCING; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; OSTEOBLAST; PHENOTYPE; PROMOTER REGION; RNA INTERFERENCE; STEM CELL; TOOTH DEVELOPMENT; TOOTH PULP;

DPSC; HDAC; OSTEOGENESIS; VALPROIC ACID;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; DENTAL PULP; DOWN-REGULATION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOCALCIN; OSTEOPONTIN; TRANSFECTION; VALPROIC ACID;

EID: 84891676752     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.1544     Document Type: Article

References (44)

1. Gronthos S, Mankani M, Brahim J et al. Postnatal human dental pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA 2000;97:13625-13630.
2. Laino G, Graziano A, d'Aquino R et al. An approachable human adult stem cell source for hard tissue engineering. J Cell Physiol 2006;206:693-701.
3. Laino G, d'Aquino R, Graziano A et al. A new population of human adult dental pulp stem cells: A useful source of living autologous fibrous bone tissue (LAB). J Bone Mineral Res 2005;20:1394-1402.
4. Paino F, Ricci G, De Rosa A et al. Ectomesenchymal stem cells from dental pulp are committed to differentiate into active melanocytes. Eur Cell Mater 2010;20:295-305.
5. Zhang W, Walboomers XF, Shi S et al. Multilineage differentiation potential of stem cells derived from human dental pulp after cryopreservation. Tissue Eng 2006;12:2813-2823.
6. Papaccio G, Graziano A, d'Aquino R et al. Long-term cryopreservation of dental pulp stem cells (SBP-DPSCs) and their differentiated osteoblasts: A cell source for tissue repair. J Cell Physiol 2006;208:319-325.
7. d'Aquino R, Graziano A, Sampaolesi M et al. Human postnatal dental pulp cells codifferentiate into osteoblasts and endotheliocytes: A pivotal synergy leading to adult bone tissue formation. Cell Death Differ 2007;14:1162-1171.
8. d'Aquino R, De Rosa A, Lanza V et al. Human mandible bone defect repair by the grafting of dental pulp stem/progenitor cells and collagen sponge biocomplexes. Eur Cell Mater 2009;18:75-83.
9. Giuliani A, Manescu A, Langer M et al. Three years after transplants in human mandibles, histological and in-line holotomography revealed that stem cells regenerated a compact rather than a spongy bone: Biological and clinical implications. Stem Cells Transl Med 2013;2:316-324.
10. Legube G, Legube D. Regulating histone acetyltransferases and deacetylases. EMBO Rep 2003;4:944-947.
11. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20:615-626.
12. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat Rev Genet 2009;10:32-42.
13. North BJ, Marshall BL, Borra MT et al. The human Sir2 ortholog, SIRT2, is an NAD1-dependent tubulin deacetylase. Mol Cell 2003;11:437-444.
14. Onyango P, Celic I, McCaffery JM et al. SIRT3, a human SIR2 homologue, is an NADdependent deacetylase localized to mitochondria. Proc Natl Acad Sci USA 2002;99: 13653-13658.
15. Witt O, Deubzer HE, Milde T et al. HDAC family: What are the cancer relevant targets? Cancer Lett 2009;277:8-21.
16. Rodriguez-Menendez V, Tremolizzo L, Cavaletti G. Targeting cancer and neuropathy with histone deacetylase inhibitors: Two birds with one stone? Curr Cancer Drug Targets 2008;8:266-274.
17. Candido EP, Reeves R, Davie JR. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 1978;14:105-113.
18. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999;96:4592-4597.
19. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-1216.
20. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nature Rev Drug Discov 2002;1:287-299.
21. Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J Bone Miner Res 2005;20:2254-2263.
22. Jeon EJ, Lee KY, Choi NS et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006;281:16502-16511.
23. Loscher W. Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16:669-694.
24. Göttlicher M, Minucci S, Zhu P et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
25. Gregory CA, Gunn WG, Peister A et al. An Alizarin red-based assay of mineralization by adherent cells in culture: Comparison with cetylpyridinium chloride extraction. Anal Biochem 2004;329:77-84.
26. Marks PA, Dokmanovic M. Histone deacetylase inhibitors: Discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-1511.
27. Qiu L, Burgess A, Fairlie DP et al. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell 2000;11:2069-2083.
28. Poon RYC, Jiang W, Toyoshima H et al. Cyclin-dependent kinases are inactivated by a combination of p21 and Thr14/Tyr15 phosphorylation after UV-induced DNA damage. J Biol Chem 1996;271:13283-13291.
29. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993;4:897-906.
30. Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307:720-728.
31. Khan N, Jeffers M, Kumar S et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-589.
32. Rodan SB, Imai Y, Thiede MA et al. Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. Cancer Res 1987;47:4961-4966.
33. Hausser HJ, Brenner RE. Phenotypic instability of Saos-2 cells in long-term culture. Biochem Biophys Res Commun 2005; 333:216-222.
34. Shafa M, Krawetz R, Rancourt DE. Returning to the stem state: Epigenetics of recapitulating pre-differentiation chromatin structure. Bioessays 2010;32:791-799.
35. Shao Y, Gao Z, Marks PA et al. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 2004;101:18030-18035.
36. Schroeder TM, Kahler RA, Li X et al. Histone deacetylase 3 interacts with runx2 to repress the osteocalcin promoter and regulate osteoblast differentiation. J Biol Chem 2004;279:41998-42007.
37. Westendorf JJ, Zaidi SK, Cascino JE et al. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/ WAF1) promoter. Mol Cell Biol 2002;22: 7982-7992.
38. Jensen ED, Schroeder TM, Bailey J et al. Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner. J Bone Miner Res 2008;23:361-372.
39. Lee HW, Suh JH, Kim AY et al. Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. Mol Endocrinol 2006;20:2432-2443.
40. Shen J, Montecino M, Lian JB et al. Histone acetylation in vivo at the osteocalcin locus is functionally linked to vitamin ddependent, bone tissue-specific transcription. J Biol Chem 2002;277:20284-20292.
41. Krämer OH, Zhu P, Ostendorff HP et al. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003;22:3411-3420.
42. Hauschka PV, Lian JB, Cole DE et al. Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone. Physiol Rev 1989;69:990-1047.
43. Boluk A, Guzelipek M, Savli H et al. The effect of valproate on bone mineral density in adult epileptic patients. Pharmacol Res 2004;50:93-97.
44. Tatsumi S, Ishii K, Amizuka N et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007;5:464-475.